Print Page  Close Window
Meridian Bioscience Appoints James M. Anderson to Board of Directors

CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has appointed James M. Anderson to its Board of Directors effective immediately.

Mr. Anderson is President and Chief Executive Officer of Cincinnati Children’s Hospital Medical Center. His appointment as President and CEO in 1996 followed 20 years of service to the Cincinnati Children’s board of trustees, including four years as chairman, as well as involvement on the Executive, Finance, Investment and Compensation, Personnel and Nominating committees. He was recently appointed chairman of the Board of the Cincinnati Branch of the Federal Reserve Bank of Cleveland.

Prior to joining the staff of Cincinnati Children’s, Mr. Anderson was a partner in the general corporate department at Taft, Stettinius & Hollister for 24 years (1968-1977; 1982-96) and president of US operations at Xomox Corporation (1977-82), a publicly traded manufacturer of specialty process controls. His extensive civic involvement includes service to the Dan Beard Council of the Boy Scouts of America, Cincinnati Museum of Natural History and the College of Mt. St. Joseph, Monarch Foundation. In May 2005, Mr. Anderson was honored with the Human Relations Award presented by the Cincinnati chapter of the American Jewish Committee, in recognition of his outstanding professional contributions and his vision of a healthy Cincinnati community.

William J. Motto, Executive Chairman of the Board said, “We are pleased that Jim Anderson has accepted a seat on Meridian’s board. Jim has extensive experience in health care management and business leadership skills. His addition to our board strengthens Meridian’s ability to meet and exceed the expectations of our shareholders. We welcome Jim to our board and look forward to his input, ideas, and advice.”

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is

Source: Meridian Bioscience, Inc.

Meridian Bioscience, Inc.
John A. Kraeutler, CEO
or Melissa A. Lueke, VP, CFO